Trials / Terminated
TerminatedNCT03711279
A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma
A Multicenter, Randomized, Open, Phase 2 Trial of SHR-1210 Plus Apatinib Versus Doxorubicin (ADM) Plus Ifosfamide (IFO) in Patients With Soft Tissue Sarcoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 99 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 16 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy of SHR-1210 plus Apatinib versus AMD plus IFO in participants with soft tissue sarcoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1210 plus Apatinib | SHR-1210 200 mg q3w+ Apatinib 500 mg qd |
| DRUG | ADM plus IFO or IFO alone | ADM 60 mg/m2 D1 + IFO 2 g/m2 D1-D4 q3w；if the cumulative doses of ADM were beyond 450 mg/m2, the monotherapy of IFO (2 g/m2 D1-D5 q3w) would be used. |
Timeline
- Start date
- 2018-11-22
- Primary completion
- 2021-06-21
- Completion
- 2021-06-21
- First posted
- 2018-10-18
- Last updated
- 2024-02-29
- Results posted
- 2024-02-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03711279. Inclusion in this directory is not an endorsement.